<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Thorax</journal-id><journal-id journal-id-type="iso-abbrev">Thorax</journal-id><journal-id journal-id-type="hwp">thoraxjnl</journal-id><journal-id journal-id-type="publisher-id">thorax</journal-id><journal-title-group><journal-title>Thorax</journal-title></journal-title-group><issn pub-type="ppub">0040-6376</issn><issn pub-type="epub">1468-3296</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24092567</article-id><article-id pub-id-type="pmc">3913208</article-id><article-id pub-id-type="publisher-id">thoraxjnl-2013-203557</article-id><article-id pub-id-type="doi">10.1136/thoraxjnl-2013-203557</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject></subj-group><subj-group subj-group-type="heading"><subject>Asthma</subject></subj-group><series-title>Original article</series-title></article-categories><title-group><article-title>Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lazarinis</surname><given-names>Nikolaos</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jørgensen</surname><given-names>Leif</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ekström</surname><given-names>Tommy</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bjermer</surname><given-names>Leif</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Dahlén</surname><given-names>Barbro</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pullerits</surname><given-names>Teet</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hedlin</surname><given-names>Gunilla</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Carlsen</surname><given-names>Kai-Håkon</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Larsson</surname><given-names>Kjell</given-names></name><xref ref-type="aff" rid="af7">7</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Division of Respiratory Medicine and Allergy, Department of Medicine</addr-line>, <institution>Karolinska University Hospital Huddinge, Karolinska Institutet</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country></aff><aff id="af2"><label>2</label><institution>AstraZeneca Nordic, Södertälje</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country></aff><aff id="af3"><label>3</label><addr-line>Department of Respiratory Medicine &amp; Allergology</addr-line>, <institution>Lund University Hospital</institution>, <addr-line>Lund</addr-line>, <country>Sweden</country></aff><aff id="af4"><label>4</label><addr-line>Department of Respiratory Medicine and Allergology</addr-line>, <institution>Sahlgrenska University Hospital</institution>, <addr-line>Göteborg</addr-line>, <country>Sweden</country></aff><aff id="af5"><label>5</label><institution>Astrid Lindgren's Children's Hospital, Karolinska University Hospital Solna</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country></aff><aff id="af6"><label>6</label><addr-line>Department of Paediatrics</addr-line>, <institution>Norwegian School of Sports Sciences, University of Oslo, Oslo University Hospital</institution>, <addr-line>Oslo</addr-line>, <country>Norway</country></aff><aff id="af7"><label>7</label><addr-line>Unit of Lung and Allergy Research</addr-line>, <institution>The National Institute of Environmental Medicine, Karolinska Institutet</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country></aff><author-notes><corresp><label>Correspondence to</label> Dr Nikolaos Lazarinis, Division of Respiratory Medicine and Allergy, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm 14186, Sweden; <email>nikolaos.lazarinis@ki.se</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>3</day><month>10</month><year>2013</year></pub-date><volume>69</volume><issue>2</issue><fpage>130</fpage><lpage>136</lpage><history><date date-type="received"><day>2</day><month>4</month><year>2013</year></date><date date-type="rev-recd"><day>27</day><month>8</month><year>2013</year></date><date date-type="accepted"><day>5</day><month>9</month><year>2013</year></date></history><permissions><copyright-statement>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access"><license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="thoraxjnl-2013-203557.pdf"></self-uri><abstract><sec><title><offsets xml_i="6120" xml_f="6130" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="6141" xml_f="6245" txt_i="22" txt_f="126">In mild asthma exercise-induced bronchoconstriction (EIB) is usually treated with inhaled short-acting β</offsets><sub><offsets xml_i="6250" xml_f="6251" txt_i="126" txt_f="127">2</offsets></sub><offsets xml_i="6257" xml_f="6285" txt_i="127" txt_f="155"> agonists (SABAs) on demand.</offsets></p></sec><sec><title><offsets xml_i="6307" xml_f="6316" txt_i="157" txt_f="166">Objective</offsets></title><p><offsets xml_i="6327" xml_f="6520" txt_i="167" txt_f="360">The hypothesis was that a combination of budesonide and formoterol on demand diminishes EIB equally to regular inhalation of budesonide and is more effective than terbutaline inhaled on demand.</offsets></p></sec><sec><title><offsets xml_i="6542" xml_f="6549" txt_i="362" txt_f="369">Methods</offsets></title><p><offsets xml_i="6560" xml_f="7064" txt_i="370" txt_f="871">Sixty-six patients with asthma (&gt;12 years of age) with verified EIB were randomised to terbutaline (0.5 mg) on demand, regular budesonide (400 μg) and terbutaline (0.5 mg) on demand, or a combination of budesonide (200 μg)  + formoterol (6 μg) on demand in a 6-week, double-blind, parallel-group study (ClinicalTrials.gov identifier: NCT00989833). The patients were instructed to perform three to four working sessions per week. The main outcome was EIB 24 h after the last dosing of study medication.</offsets></p></sec><sec><title><offsets xml_i="7086" xml_f="7093" txt_i="873" txt_f="880">Results</offsets></title><p><offsets xml_i="7104" xml_f="7653" txt_i="881" txt_f="1430">After 6 weeks of treatment with regular budesonide or budesonide+formoterol on demand the maximum post-exercise forced expiratory volume in 1 s fall, 24 h after the last medication, was 6.6% (mean; 95% CI −10.3 to −3.0) and 5.4% (−8.9 to −1.8) smaller, respectively. This effect was superior to inhalation of terbutaline on demand (+1.5%; −2.1 to +5.1). The total budesonide dose was approximately 2.5 times lower in the budesonide+formoterol group than in the regular budesonide group. The need for extra medication was similar in the three groups.</offsets></p></sec><sec><title><offsets xml_i="7675" xml_f="7686" txt_i="1432" txt_f="1443">Conclusions</offsets></title><p><offsets xml_i="7697" xml_f="8129" txt_i="1444" txt_f="1876">The combination of budesonide and formoterol on demand improves asthma control by reducing EIB in the same order of magnitude as regular budesonide treatment despite a substantially lower total steroid dose. Both these treatments were superior to terbutaline on demand, which did not alter the bronchial response to exercise. The results question the recommendation of prescribing SABAs as the only treatment for EIB in mild asthma.</offsets></p></sec></abstract><kwd-group><kwd>Asthma</kwd><kwd>Exercise</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text position="float"><caption><title><offsets xml_i="8420" xml_f="8432" txt_i="1885" txt_f="1897">Key messages</offsets></title></caption><sec><title><offsets xml_i="8462" xml_f="8487" txt_i="1898" txt_f="1923">What is the key question?</offsets></title><list list-type="bullet"><list-item><p><offsets xml_i="8534" xml_f="8686" txt_i="1924" txt_f="2076">Does on-demand treatment with the combination of budesonide/formoterol improve asthma control as assessed by exercise induced bronchoconstriction (EIB)?</offsets></p></list-item></list></sec><sec><title><offsets xml_i="8727" xml_f="8751" txt_i="2078" txt_f="2102">What is the bottom line?</offsets></title><list list-type="bullet"><list-item><p><offsets xml_i="8798" xml_f="8868" txt_i="2103" txt_f="2173">The combination of an inhaled corticosteroid (ICS) and a long-acting β</offsets><sub><offsets xml_i="8873" xml_f="8874" txt_i="2173" txt_f="2174">2</offsets></sub><offsets xml_i="8880" xml_f="8956" txt_i="2174" txt_f="2250"> agonist (LABA) on demand yields better asthma control than a short-acting β</offsets><sub><offsets xml_i="8961" xml_f="8962" txt_i="2250" txt_f="2251">2</offsets></sub><offsets xml_i="8968" xml_f="9039" txt_i="2251" txt_f="2322"> agonist (SABA) on demand and is non-inferior to regular ICS treatment.</offsets></p></list-item></list></sec><sec><title><offsets xml_i="9080" xml_f="9092" txt_i="2324" txt_f="2336">Why read on?</offsets></title><list list-type="bullet"><list-item><p><offsets xml_i="9139" xml_f="9522" txt_i="2337" txt_f="2720">Current recommendations of treating EIB with a SABA on demand as the only medication in patients with mild asthma does not improve bronchial response to exercise over time and could therefore be questioned. On-demand treatment with an ICS/LABA combination improves asthma control and should be considered as an alternative in patients who otherwise would be treated with regular ICS.</offsets></p></list-item></list></sec></boxed-text><sec id="s1"><title><offsets xml_i="9584" xml_f="9596" txt_i="2722" txt_f="2734">Introduction</offsets></title><p><offsets xml_i="9607" xml_f="9679" txt_i="2735" txt_f="2807">Exercise-induced bronchoconstriction (EIB) is a common feature in asthma</offsets><xref rid="R1" ref-type="bibr"><offsets xml_i="9710" xml_f="9711" txt_i="2807" txt_f="2808">1</offsets></xref><offsets xml_i="9718" xml_f="9795" txt_i="2808" txt_f="2885"> and exercise-induced symptoms constitute a substantial impact on daily life.</offsets><xref rid="R2" ref-type="bibr"><offsets xml_i="9826" xml_f="9827" txt_i="2885" txt_f="2886">2</offsets></xref><offsets xml_i="9834" xml_f="9915" txt_i="2886" txt_f="2967"> Asthma medications reduce exercise-induced symptoms and improve physical fitness</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="9946" xml_f="9947" txt_i="2967" txt_f="2968">3</offsets></xref><offsets xml_i="9954" xml_f="10022" txt_i="2968" txt_f="3036"> but, despite treatment being given according to current guidelines,</offsets><xref rid="R1" ref-type="bibr"><offsets xml_i="10053" xml_f="10054" txt_i="3036" txt_f="3037">1</offsets></xref><offsets xml_i="10061" xml_f="10145" txt_i="3037" txt_f="3121"> many patients with asthma experience symptoms in connection with physical exercise.</offsets></p><p><offsets xml_i="10152" xml_f="10201" txt_i="3122" txt_f="3171">In current recommendations short-acting inhaled β</offsets><sub><offsets xml_i="10206" xml_f="10207" txt_i="3171" txt_f="3172">2</offsets></sub><offsets xml_i="10213" xml_f="10386" txt_i="3172" txt_f="3345"> agonists (SABAs) are advocated for patients who experience EIB despite otherwise controlled asthma and in patients in whom exercise is the only trigger for asthma symptoms.</offsets><xref rid="R1" ref-type="bibr"><offsets xml_i="10417" xml_f="10418" txt_i="3345" txt_f="3346">1</offsets></xref><offsets xml_i="10425" xml_f="10491" txt_i="3346" txt_f="3412"> In patients with insufficient disease control, despite inhaling β</offsets><sub><offsets xml_i="10496" xml_f="10497" txt_i="3412" txt_f="3413">2</offsets></sub><offsets xml_i="10503" xml_f="10636" txt_i="3413" txt_f="3546"> agonists prior to exercise, the addition of controller medications, inhaled glucocorticosteroids or antileukotrienes is recommended.</offsets><xref rid="R1" ref-type="bibr"><offsets xml_i="10667" xml_f="10668" txt_i="3546" txt_f="3547">1</offsets></xref><offsets xml_i="10675" xml_f="10779" txt_i="3547" txt_f="3651"> In real-life practice it may be difficult to determine when controller medication should be introduced.</offsets></p><p><offsets xml_i="10786" xml_f="10886" txt_i="3652" txt_f="3752">Inhalation of β agonists, prior to exercise or when EIB has occurred, reduces or even abolishes EIB.</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="10917" xml_f="10918" txt_i="3752" txt_f="3753">4</offsets></xref><offsets xml_i="10925" xml_f="10980" txt_i="3753" txt_f="3808"> During continuous treatment the protective effect of β</offsets><sub><offsets xml_i="10985" xml_f="10986" txt_i="3808" txt_f="3809">2</offsets></sub><offsets xml_i="10992" xml_f="11129" txt_i="3809" txt_f="3946"> agonists against EIB diminishes with time and does not offer the same protection after a few weeks of treatment as after the first dose.</offsets><xref rid="R5" ref-type="bibr"><offsets xml_i="11160" xml_f="11161" txt_i="3946" txt_f="3947">5</offsets></xref><offsets xml_i="11168" xml_f="11169" txt_i="3947" txt_f="3948">
</offsets><xref rid="R6" ref-type="bibr"><offsets xml_i="11200" xml_f="11201" txt_i="3948" txt_f="3949">6</offsets></xref><offsets xml_i="11208" xml_f="11264" txt_i="3949" txt_f="4005"> Tachyphylaxis with regard to the protective effect of β</offsets><sub><offsets xml_i="11269" xml_f="11270" txt_i="4005" txt_f="4006">2</offsets></sub><offsets xml_i="11276" xml_f="11356" txt_i="4006" txt_f="4086"> agonists has been demonstrated for bronchoconstriction induced by methacholine,</offsets><xref rid="R5" ref-type="bibr"><offsets xml_i="11387" xml_f="11388" txt_i="4086" txt_f="4087">5</offsets></xref><offsets xml_i="11395" xml_f="11406" txt_i="4087" txt_f="4098"> adenosine,</offsets><xref rid="R6" ref-type="bibr"><offsets xml_i="11437" xml_f="11438" txt_i="4098" txt_f="4099">6</offsets></xref><offsets xml_i="11445" xml_f="11454" txt_i="4099" txt_f="4108"> exercise</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="11485" xml_f="11486" txt_i="4108" txt_f="4109">7</offsets></xref><offsets xml_i="11493" xml_f="11494" txt_i="4109" txt_f="4110">
</offsets><xref rid="R8" ref-type="bibr"><offsets xml_i="11525" xml_f="11526" txt_i="4110" txt_f="4111">8</offsets></xref><offsets xml_i="11533" xml_f="11547" txt_i="4111" txt_f="4125"> and allergen.</offsets><xref rid="R9" ref-type="bibr"><offsets xml_i="11578" xml_f="11579" txt_i="4125" txt_f="4126">9</offsets></xref></p><p><offsets xml_i="11593" xml_f="12027" txt_i="4127" txt_f="4561">The aim of this study was to evaluate the effect of three different treatment regimens on asthma control by the response to exercise not preceded by bronchodilator treatment. The aim was thus not to study the direct effect of treatment on EIB. Currently recommended treatment, that is, SABAs inhaled on demand (ie, before training and for symptom relief) was compared with regular treatment with an inhaled glucocorticosteroid and a β</offsets><sub><offsets xml_i="12032" xml_f="12033" txt_i="4561" txt_f="4562">2</offsets></sub><offsets xml_i="12039" xml_f="12141" txt_i="4562" txt_f="4664"> agonist on demand and a fixed combination of an inhaled glucocorticosteroid and a rapid long-acting β</offsets><sub><offsets xml_i="12146" xml_f="12147" txt_i="4664" txt_f="4665">2</offsets></sub><offsets xml_i="12153" xml_f="12302" txt_i="4665" txt_f="4814"> agonist (LABA) inhaled only on demand. We hypothesised that the fixed combination on demand provides better asthma control than monotherapy with a β</offsets><sub><offsets xml_i="12307" xml_f="12308" txt_i="4814" txt_f="4815">2</offsets></sub><offsets xml_i="12314" xml_f="12418" txt_i="4815" txt_f="4919"> agonist on demand and is non-inferior to regular treatment with an inhaled glucocorticosteroid with a β</offsets><sub><offsets xml_i="12423" xml_f="12424" txt_i="4919" txt_f="4920">2</offsets></sub><offsets xml_i="12430" xml_f="12449" txt_i="4920" txt_f="4939"> agonist on demand.</offsets></p></sec><sec sec-type="materials|methods" id="s2"><title><offsets xml_i="12508" xml_f="12528" txt_i="4941" txt_f="4961">Material and methods</offsets></title><sec id="s2a"><title><offsets xml_i="12557" xml_f="12569" txt_i="4962" txt_f="4974">Study design</offsets></title><p><offsets xml_i="12580" xml_f="12816" txt_i="4975" txt_f="5211">In a randomised, double-blind, double dummy, parallel-group, 6-week trial the protective effect of three treatment regimens on EIB was investigated in adults and adolescents with mild asthma. The treatment alternatives were as follows:
</offsets><list list-type="bullet"><list-item><p><offsets xml_i="12855" xml_f="13008" txt_i="5211" txt_f="5364">regular placebo once daily and a fixed combination of 200 μg budesonide and 6.0 μg formoterol metered dose (Symbicort, AstraZeneca AB, Sweden) on demand;</offsets></p></list-item><list-item><p><offsets xml_i="13038" xml_f="13138" txt_i="5365" txt_f="5465">regular placebo once daily and 500 μg terbutaline metered dose (Bricanyl, AstraZeneca AB) on demand;</offsets></p></list-item><list-item><p><offsets xml_i="13168" xml_f="13333" txt_i="5466" txt_f="5631">regular inhalation of 400 μg budesonide metered dose (Pulmicort, AstraZeneca AB) once daily and 500 μg terbutaline metered dose (Bricanyl, AstraZeneca AB) on demand.</offsets></p></list-item></list></p><p><offsets xml_i="13363" xml_f="13591" txt_i="5633" txt_f="5861">On demand means inhalation of study drugs before exercise and for symptom relief at any time. The participating subjects were instructed to perform physical exercise three to four times a week during the 6-week treatment period.</offsets></p><p><offsets xml_i="13598" xml_f="13734" txt_i="5862" txt_f="5998">The trial was conducted at 10 study sites in Sweden and Norway. All study subjects attended two screening visits prior to randomisation.</offsets></p><p><offsets xml_i="13741" xml_f="14052" txt_i="5999" txt_f="6310">At the first visit a standard skin prick test, spirometry, physical examination, vital signs control, demography, control of medical history and concomitant medication were conducted and the Asthma Control Questionnaire 5 (ACQ5) was completed. Eligible subjects underwent a maximal exercise test on a treadmill.</offsets></p><p><offsets xml_i="14059" xml_f="14203" txt_i="6311" txt_f="6455">At the second visit a 6 min standardised exercise test was performed on a treadmill at 90% of maximal aerobic capacity, while breathing dry air.</offsets><xref rid="R10" ref-type="bibr"><offsets xml_i="14235" xml_f="14237" txt_i="6455" txt_f="6457">10</offsets></xref><offsets xml_i="14244" xml_f="14298" txt_i="6457" txt_f="6511"> If post-exercise forced expiratory volume in 1 s (FEV</offsets><sub><offsets xml_i="14303" xml_f="14304" txt_i="6511" txt_f="6512">1</offsets></sub><offsets xml_i="14310" xml_f="14395" txt_i="6512" txt_f="6597">) was reduced by ≥10% compared with the pre-exercise value, the patient was included.</offsets></p><p><offsets xml_i="14402" xml_f="14589" txt_i="6598" txt_f="6785">At the third visit the patients were randomised to one of the three treatment regimens. Three weeks and 6 weeks after randomisation an exercise test, identical to visit 2, was performed (</offsets><xref ref-type="fig" rid="THORAXJNL2013203557F1"><offsets xml_i="14638" xml_f="14646" txt_i="6785" txt_f="6793">figure 1</offsets></xref><offsets xml_i="14653" xml_f="14655" txt_i="6793" txt_f="6795">).</offsets></p><fig id="THORAXJNL2013203557F1" position="float"><label><offsets xml_i="14715" xml_f="14723" txt_i="6796" txt_f="6804">Figure 1</offsets></label><caption><p><offsets xml_i="14743" xml_f="14756" txt_i="6804" txt_f="6817">Study design.</offsets></p></caption><graphic xlink:href="thoraxjnl-2013-203557f01"></graphic></fig></sec><sec id="s2b"><title><offsets xml_i="14860" xml_f="14868" txt_i="6819" txt_f="6827">Subjects</offsets></title><p><offsets xml_i="14879" xml_f="14948" txt_i="6828" txt_f="6897">Eligible subjects were outpatients ≥12 years of age with mild asthma,</offsets><xref rid="R1" ref-type="bibr"><offsets xml_i="14979" xml_f="14980" txt_i="6897" txt_f="6898">1</offsets></xref><offsets xml_i="14987" xml_f="15094" txt_i="6898" txt_f="7005"> a history of EIB and who used reliever medication for asthma symptoms up to four times per week with a FEV</offsets><sub><offsets xml_i="15099" xml_f="15100" txt_i="7005" txt_f="7006">1</offsets></sub><offsets xml_i="15106" xml_f="15140" txt_i="7006" txt_f="7037"> &gt;80% of predicted normal value</offsets><xref rid="R11" ref-type="bibr"><offsets xml_i="15172" xml_f="15174" txt_i="7037" txt_f="7039">11</offsets></xref><offsets xml_i="15181" xml_f="15182" txt_i="7039" txt_f="7040">
</offsets><xref rid="R12" ref-type="bibr"><offsets xml_i="15214" xml_f="15216" txt_i="7040" txt_f="7042">12</offsets></xref><offsets xml_i="15223" xml_f="15611" txt_i="7042" txt_f="7430"> and who performed physical exercise on a regular basis (at least three times per week). Smokers and ex-smokers who quit during the last year were excluded. Other exclusion criteria were indication for treatment with anti-inflammatory asthma medications (investigator’s judgment), use of oral corticosteroids during the month prior to the study and significant diseases other than asthma.</offsets></p><p><offsets xml_i="15618" xml_f="15884" txt_i="7431" txt_f="7697">All patients provided written informed consent. The study was approved by the Ethics Committee of Stockholm (D5890L00032) and the Regional Ethics Committee of Health Region South East of Norway. The study is registered at ClinicalTrials.gov (identifier NCT00989833).</offsets></p></sec><sec id="s2c"><title><offsets xml_i="15915" xml_f="15925" txt_i="7699" txt_f="7709">Spirometry</offsets></title><p><offsets xml_i="15936" xml_f="16051" txt_i="7710" txt_f="7825">Pulmonary function was measured according to the European Respiratory Society/American Thoracic Society guidelines.</offsets><xref rid="R13" ref-type="bibr"><offsets xml_i="16083" xml_f="16085" txt_i="7825" txt_f="7827">13</offsets></xref><offsets xml_i="16092" xml_f="16149" txt_i="7827" txt_f="7884"> The spirometers were calibrated on a daily basis. If FEV</offsets><sub><offsets xml_i="16154" xml_f="16155" txt_i="7884" txt_f="7885">1</offsets></sub><offsets xml_i="16161" xml_f="16322" txt_i="7885" txt_f="8046"> was between 75% and 80% of predicted value the spirometry was repeated 15 min after inhalation of 0.4 mg of salbutamol. If salbutamol induced an increase of FEV</offsets><sub><offsets xml_i="16327" xml_f="16328" txt_i="8046" txt_f="8047">1</offsets></sub><offsets xml_i="16334" xml_f="16436" txt_i="8047" txt_f="8143">&lt;12% of the preinhalation value and &lt;200 mL, the patient proceeded to the maximal exercise test.</offsets></p></sec><sec id="s2d"><title><offsets xml_i="16467" xml_f="16482" txt_i="8145" txt_f="8160">Skin prick test</offsets></title><p><offsets xml_i="16493" xml_f="16743" txt_i="8161" txt_f="8411">A skin prick test with 10 common allergens (ALK Abello Soluprick SQ allergen solution, Copenhagen, Denmark) was performed with histamine (10 mg/mL) as a positive and the diluent as a negative control. Positive response was specified as a wheel ≥3 mm.</offsets></p></sec><sec id="s2e"><title><offsets xml_i="16774" xml_f="16795" txt_i="8413" txt_f="8434">Maximal exercise test</offsets></title><p><offsets xml_i="16806" xml_f="17223" txt_i="8435" txt_f="8852">A maximal exercise test was performed on a treadmill while breathing ambient air according to a predefined protocol starting at 50 W, which was then increased by 10 or 15 W (depending on body weight) every minute. Heart rate was monitored by ECG and registered during the last 15 s of each workload level. Dyspnoea and leg fatigue were registered according to the Borg CentiMax scale (CR100) at every second workload.</offsets><xref rid="R14" ref-type="bibr"><offsets xml_i="17255" xml_f="17257" txt_i="8852" txt_f="8854">14</offsets></xref><offsets xml_i="17264" xml_f="17341" txt_i="8854" txt_f="8931"> Maximal heart rate and the workload at the time of stopping were registered.</offsets></p></sec><sec id="s2f"><title><offsets xml_i="17372" xml_f="17398" txt_i="8933" txt_f="8959">Standardised exercise test</offsets></title><p><offsets xml_i="17409" xml_f="17707" txt_i="8960" txt_f="9258">A 6 min standardised exercise test was performed at approximately 90% of maximal aerobic capacity (based on the maximal exercise test at visit 1) while breathing dry air (Aiolos Astmatest, Aiolos Medical AB, Karlstad, Sweden). Exercise was identically performed on a treadmill at visits 2, 4 and 5.</offsets><xref rid="R10" ref-type="bibr"><offsets xml_i="17739" xml_f="17741" txt_i="9258" txt_f="9260">10</offsets></xref><offsets xml_i="17748" xml_f="17874" txt_i="9260" txt_f="9386"> During exercise the patients wore a nose clip and breathed through a tube connected to a gas cylinder containing dry air. FEV</offsets><sub><offsets xml_i="17879" xml_f="17880" txt_i="9386" txt_f="9387">1</offsets></sub><offsets xml_i="17886" xml_f="18098" txt_i="9387" txt_f="9596"> was measured 15 min before exercise and 1, 5, 10, 15 and 30 min after conclusion of the exercise after which terbutaline was inhaled (2 mg in patients ≥15 years old and 1 mg in patients &lt;15 years old) and FEV</offsets><sub><offsets xml_i="18103" xml_f="18104" txt_i="9596" txt_f="9597">1</offsets></sub><offsets xml_i="18110" xml_f="18137" txt_i="9597" txt_f="9624"> was measured 15 min later.</offsets></p><p><offsets xml_i="18144" xml_f="18338" txt_i="9625" txt_f="9819">If the exercise test at visits 4 or 5 was finished before the stipulated endpoint defined at visit 2, the patient was rescheduled another test or excluded from the study (investigator’s choice).</offsets></p><p><offsets xml_i="18345" xml_f="18559" txt_i="9820" txt_f="10034">No asthma drugs were allowed 24 h prior to the exercise tests. Patients were instructed to perform physical exercise 24–48 h before and to abstain from physical exercise during the 24 h prior to the exercise tests.</offsets></p></sec><sec id="s2g"><title><offsets xml_i="18590" xml_f="18624" txt_i="10036" txt_f="10070">Diary recording of asthma symptoms</offsets></title><p><offsets xml_i="18635" xml_f="18935" txt_i="10071" txt_f="10371">At the third visit the patients gained access to an electronic diary (uniform resource locator (URL)) to record physical activities, asthma symptoms and use of as-needed medication on a daily basis. Asthma symptoms were rated on a scale from 1 to 5, with higher scores indicating less asthma control.</offsets></p><p><offsets xml_i="18942" xml_f="19012" txt_i="10372" txt_f="10442">A shortened version of the ACQ5 was completed at visits 1, 3, 4 and 6.</offsets><xref rid="R15" ref-type="bibr"><offsets xml_i="19044" xml_f="19046" txt_i="10442" txt_f="10444">15</offsets></xref></p></sec><sec id="s2h"><title><offsets xml_i="19084" xml_f="19100" txt_i="10446" txt_f="10462">Outcome measures</offsets></title><p><offsets xml_i="19111" xml_f="19195" txt_i="10463" txt_f="10547">The primary outcome variable was the change in maximal post-exercise decrease of FEV</offsets><sub><offsets xml_i="19200" xml_f="19201" txt_i="10547" txt_f="10548">1</offsets></sub><offsets xml_i="19207" xml_f="19386" txt_i="10548" txt_f="10727"> following a standardised exercise test, performed after 6 weeks of treatment, without any medication during the 24 h prior to the test, and compared with the pretreatment result.</offsets></p><p><offsets xml_i="19393" xml_f="19469" txt_i="10728" txt_f="10804">Secondary outcome variables were the alteration of maximal post-exercise FEV</offsets><sub><offsets xml_i="19474" xml_f="19475" txt_i="10804" txt_f="10805">1</offsets></sub><offsets xml_i="19481" xml_f="19615" txt_i="10805" txt_f="10939"> fall after 3 weeks, ACQ5, patient-reported symptoms and use of study drugs inhaled prior to training sessions and for symptom relief.</offsets></p><p><offsets xml_i="19622" xml_f="19748" txt_i="10940" txt_f="11066">Safety outcome measures included adverse events, serious adverse events and changes in vital signs (pulse and blood pressure).</offsets></p></sec><sec id="s2i"><title><offsets xml_i="19779" xml_f="19799" txt_i="11068" txt_f="11088">Statistical analyses</offsets></title><p><offsets xml_i="19810" xml_f="19889" txt_i="11089" txt_f="11168">Results are presented as mean±SD or 95% CI. Maximal change in post-exercise FEV</offsets><sub><offsets xml_i="19894" xml_f="19895" txt_i="11168" txt_f="11169">1</offsets></sub><offsets xml_i="19901" xml_f="20054" txt_i="11169" txt_f="11322"> before and after 6 weeks of treatment was analysed by analysis of covariance, with treatment as a factor and the baseline value of the post-exercise FEV</offsets><sub><offsets xml_i="20059" xml_f="20060" txt_i="11322" txt_f="11323">1</offsets></sub><offsets xml_i="20066" xml_f="20249" txt_i="11323" txt_f="11506"> before treatment as the covariate. Secondary variables were similarly analysed and used to evaluate the protective effect of the treatments over time. All analyses were prespecified.</offsets></p><p><offsets xml_i="20256" xml_f="20477" txt_i="11507" txt_f="11728">Based on previous results, a non-inferiority limit for the comparison between the protection against EIB in the formoterol/budesonide group and the regular budesonide group was defined as a difference in post-exercise FEV</offsets><sub><offsets xml_i="20482" xml_f="20483" txt_i="11728" txt_f="11729">1</offsets></sub><offsets xml_i="20489" xml_f="20505" txt_i="11729" txt_f="11742"> fall &lt;7.28%.</offsets><xref rid="R16" ref-type="bibr"><offsets xml_i="20537" xml_f="20539" txt_i="11742" txt_f="11744">16</offsets></xref><offsets xml_i="20546" xml_f="20689" txt_i="11744" txt_f="11887"> Non-inferiority analysis was based on a sample size of 66 randomised patients, with 80% power, assuming a SD of 7.13 (estimated from Jonasson </offsets><italic><offsets xml_i="20697" xml_f="20702" txt_i="11887" txt_f="11892">et al</offsets></italic><xref rid="R16" ref-type="bibr"><offsets xml_i="20743" xml_f="20745" txt_i="11892" txt_f="11894">16</offsets></xref><offsets xml_i="20752" xml_f="20954" txt_i="11894" txt_f="12096">) with a 5% significance level. Statistical analyses were performed using SAS V.9.2 (SAS Institute Inc). Randomisation envelopes were generated by a central randomisation system (GRAND, AstraZeneca AB).</offsets></p></sec></sec><sec sec-type="results" id="s3"><title><offsets xml_i="21009" xml_f="21016" txt_i="12099" txt_f="12106">Results</offsets></title><sec id="s3a"><title><offsets xml_i="21045" xml_f="21082" txt_i="12107" txt_f="12144">Patients and baseline characteristics</offsets></title><p><offsets xml_i="21093" xml_f="21312" txt_i="12145" txt_f="12364">Patients were enrolled from September 2009 to July 2010. A total of 189 patients were assessed for eligibility, of whom 66 were randomised and allocated to study treatment. Reasons for exclusion were a post-exercise FEV</offsets><sub><offsets xml_i="21317" xml_f="21318" txt_i="12364" txt_f="12365">1</offsets></sub><offsets xml_i="21324" xml_f="21371" txt_i="12365" txt_f="12409"> fall &lt;10% at visit 2 (n=94), a baseline FEV</offsets><sub><offsets xml_i="21376" xml_f="21377" txt_i="12409" txt_f="12410">1</offsets></sub><offsets xml_i="21383" xml_f="21556" txt_i="12410" txt_f="12580"> &lt; 80% of predicted value at visit 1 (n=9), other diseases (n=8), clear need for continuous treatment with inhaled steroids (n=6) and other, not specified, reasons (n=6).</offsets></p><p><offsets xml_i="21563" xml_f="22036" txt_i="12581" txt_f="13054">Primary outcome data were available at visit 5 in 59 patients. Results and safety analyses from patients with missing data at visit 5 (n=7) were carried forward from visit 4 and included in the full analysis set of 66 patients. Four of these patients were excluded from the per protocol analysis set, three in the budesonide group due to non-compliance with maintenance budesonide treatment and one in the budesonide+formoterol group who took extra medication on most days.</offsets></p><p><offsets xml_i="22043" xml_f="22084" txt_i="13055" txt_f="13096">Patient characteristics are presented in </offsets><xref ref-type="table" rid="THORAXJNL2013203557TB1"><offsets xml_i="22136" xml_f="22143" txt_i="13096" txt_f="13103">table 1</offsets></xref><offsets xml_i="22150" xml_f="22296" txt_i="13103" txt_f="13249">. There were more ex-smokers in the budesonide/formoterol group than in the other groups, but lung function did not differ between ex-smokers (FEV</offsets><sub><offsets xml_i="22301" xml_f="22302" txt_i="13249" txt_f="13250">1</offsets></sub><offsets xml_i="22308" xml_f="22343" txt_i="13250" txt_f="13285"> 99.4±11.9% of predicted value; FEV</offsets><sub><offsets xml_i="22348" xml_f="22349" txt_i="13285" txt_f="13286">1</offsets></sub><offsets xml_i="22355" xml_f="22417" txt_i="13286" txt_f="13348">/forced vital capacity (FVC) 0.81±0.06) and never-smokers (FEV</offsets><sub><offsets xml_i="22422" xml_f="22423" txt_i="13348" txt_f="13349">1</offsets></sub><offsets xml_i="22429" xml_f="22464" txt_i="13349" txt_f="13384"> 98.6±10.2% of predicted value; FEV</offsets><sub><offsets xml_i="22469" xml_f="22470" txt_i="13384" txt_f="13385">1</offsets></sub><offsets xml_i="22476" xml_f="22625" txt_i="13385" txt_f="13534">/FVC 0.80±0.08). Relevant medical conditions other than asthma were found in 27 patients (most commonly, allergic rhino-conjunctivitis and rhinitis).</offsets></p><table-wrap id="THORAXJNL2013203557TB1" position="float"><label><offsets xml_i="22693" xml_f="22700" txt_i="13535" txt_f="13542">Table 1</offsets></label><caption><p><offsets xml_i="22720" xml_f="22765" txt_i="13542" txt_f="13587">Patient characteristics at baseline (visit 1)</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="23046" xml_f="23061" txt_i="13588" txt_f="13603">Characteristics</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="23107" xml_f="23165" txt_i="13603" txt_f="13661">Regular placebo once daily+budesonide/formoterol on demand</offsets><break></break><offsets xml_i="23180" xml_f="23184" txt_i="13661" txt_f="13665">N=23</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="23230" xml_f="23278" txt_i="13665" txt_f="13713">Regular placebo once daily+terbutaline on demand</offsets><break></break><offsets xml_i="23293" xml_f="23297" txt_i="13713" txt_f="13717">N=22</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="23343" xml_f="23394" txt_i="13717" txt_f="13768">Regular budesonide once daily+terbutaline on demand</offsets><break></break><offsets xml_i="23409" xml_f="23413" txt_i="13768" txt_f="13772">N=21</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="23470" xml_f="23481" txt_i="13772" txt_f="13783">Age (years)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23514" xml_f="23519" txt_i="13784" txt_f="13789">31±12</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23552" xml_f="23557" txt_i="13790" txt_f="13795">28±12</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23590" xml_f="23595" txt_i="13796" txt_f="13801">26±10</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23637" xml_f="23646" txt_i="13802" txt_f="13811">Women/men</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23679" xml_f="23683" txt_i="13812" txt_f="13816">9/14</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23716" xml_f="23720" txt_i="13817" txt_f="13821">16/6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23753" xml_f="23758" txt_i="13822" txt_f="13827">11/10</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23800" xml_f="23809" txt_i="13828" txt_f="13837">BMI (kg/m</offsets><sup><offsets xml_i="23814" xml_f="23815" txt_i="13837" txt_f="13838">2</offsets></sup><offsets xml_i="23821" xml_f="23822" txt_i="13838" txt_f="13839">)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23855" xml_f="23863" txt_i="13840" txt_f="13848">25.0±4.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23896" xml_f="23904" txt_i="13849" txt_f="13857">23.4±3.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23937" xml_f="23945" txt_i="13858" txt_f="13866">24.6±3.6</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23987" xml_f="24001" txt_i="13867" txt_f="13881">Ex-smokers (n)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24034" xml_f="24035" txt_i="13882" txt_f="13883">8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24068" xml_f="24069" txt_i="13884" txt_f="13885">1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24102" xml_f="24103" txt_i="13886" txt_f="13887">1</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24145" xml_f="24170" txt_i="13888" txt_f="13913">Smoking cessation (years)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24203" xml_f="24210" txt_i="13914" txt_f="13921">7.1±5.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24243" xml_f="24250" txt_i="13922" txt_f="13929">3.4±0.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24283" xml_f="24290" txt_i="13930" txt_f="13937">7.2±0.0</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24332" xml_f="24335" txt_i="13938" txt_f="13941">FEV</offsets><sub><offsets xml_i="24340" xml_f="24341" txt_i="13941" txt_f="13942">1</offsets></sub><offsets xml_i="24347" xml_f="24360" txt_i="13942" txt_f="13955"> baseline (L)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24393" xml_f="24400" txt_i="13956" txt_f="13963">3.8±0.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24433" xml_f="24440" txt_i="13964" txt_f="13971">3.4±0.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24473" xml_f="24480" txt_i="13972" txt_f="13979">3.8±0.8</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24522" xml_f="24525" txt_i="13980" txt_f="13983">FEV</offsets><sub><offsets xml_i="24530" xml_f="24531" txt_i="13983" txt_f="13984">1</offsets></sub><offsets xml_i="24537" xml_f="24555" txt_i="13984" txt_f="14002"> % predicted value</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24588" xml_f="24594" txt_i="14003" txt_f="14009">100±12</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24627" xml_f="24632" txt_i="14010" txt_f="14015">97±10</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24665" xml_f="24669" txt_i="14016" txt_f="14020">99±9</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24711" xml_f="24743" txt_i="14021" txt_f="14053">Positive skin prick test (n (%))</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24776" xml_f="24783" txt_i="14054" txt_f="14061">14 (61)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24816" xml_f="24823" txt_i="14062" txt_f="14069">16 (73)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24856" xml_f="24863" txt_i="14070" txt_f="14077">15 (71)</offsets></td></tr><tr><td colspan="4" rowspan="1"><offsets xml_i="24905" xml_f="24926" txt_i="14078" txt_f="14099">Maximal exercise test</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24968" xml_f="24985" txt_i="14100" txt_f="14117"> Max workload (W)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25018" xml_f="25024" txt_i="14118" txt_f="14124">251±66</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25057" xml_f="25063" txt_i="14125" txt_f="14131">232±57</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25096" xml_f="25102" txt_i="14132" txt_f="14138">255±63</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25144" xml_f="25170" txt_i="14139" txt_f="14165"> Max dyspnoea (Borg CR100)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25203" xml_f="25212" txt_i="14166" txt_f="14175">86.5±20.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25245" xml_f="25254" txt_i="14176" txt_f="14185">95.9±21.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25287" xml_f="25296" txt_i="14186" txt_f="14195">85.3±25.5</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25338" xml_f="25367" txt_i="14196" txt_f="14225"> Max leg fatigue (Borg CR100)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25400" xml_f="25409" txt_i="14226" txt_f="14235">77.0±25.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25442" xml_f="25451" txt_i="14236" txt_f="14245">87.3±23.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25484" xml_f="25493" txt_i="14246" txt_f="14255">79.1±26.5</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25535" xml_f="25562" txt_i="14256" txt_f="14283"> Max heart rate (beats/min)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25595" xml_f="25600" txt_i="14284" txt_f="14289">186±9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25633" xml_f="25639" txt_i="14290" txt_f="14296">189±12</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25672" xml_f="25678" txt_i="14297" txt_f="14303">181±25</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="25728" xml_f="25844" txt_i="14304" txt_f="14420">Data are presented as mean±SD. On demand means medication inhaled prior to training sessions and for symptom relief.</offsets></p></fn><fn><p><offsets xml_i="25860" xml_f="25885" txt_i="14421" txt_f="14446">BMI, body mass index; FEV</offsets><sub><offsets xml_i="25890" xml_f="25891" txt_i="14446" txt_f="14447">1</offsets></sub><offsets xml_i="25897" xml_f="25931" txt_i="14447" txt_f="14481">, forced expiratory volume in 1 s.</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title><offsets xml_i="25998" xml_f="26012" txt_i="14483" txt_f="14497">Exercise tests</offsets></title><p><offsets xml_i="26023" xml_f="26267" txt_i="14498" txt_f="14742">The maximal workload at the maximal exercise test was 246.4±61.7 W. Mean maximal leg fatigue Borg score was 81.0±24.0 and the maximal dyspnoea score was 89.1±22.4, indicating breathlessness limiting physical performance rather than leg fatigue.</offsets></p><p><offsets xml_i="26274" xml_f="26363" txt_i="14743" txt_f="14832">Compared with the exercise test performed before treatment, the maximum post-exercise FEV</offsets><sub><offsets xml_i="26368" xml_f="26369" txt_i="14832" txt_f="14833">1</offsets></sub><offsets xml_i="26375" xml_f="26628" txt_i="14833" txt_f="15086"> fall after 6 weeks of treatment was 5.4% (mean; 95% CI −8.9 to −1.8) smaller in the budesonide/ formoterol on-demand group, 6.6% (−10.3 to −3.0) smaller in the regular budesonide group and 1.5% (−2.1 to+5.1) greater in the terbutaline on-demand group (</offsets><xref ref-type="table" rid="THORAXJNL2013203557TB2"><offsets xml_i="26680" xml_f="26687" txt_i="15086" txt_f="15093">table 2</offsets></xref><offsets xml_i="26694" xml_f="26696" txt_i="15093" txt_f="15095">, </offsets><xref ref-type="fig" rid="THORAXJNL2013203557F2"><offsets xml_i="26745" xml_f="26753" txt_i="15095" txt_f="15103">figure 2</offsets></xref><offsets xml_i="26760" xml_f="27000" txt_i="15103" txt_f="15343">). Compared with pretreatment results, EIB was reduced by 28.5% in the budesonide/formoterol on-demand group and by 38.6% in the regular budesonide group, and increased by 8.9% in the terbutaline on-demand group after 6 weeks of treatment (</offsets><xref ref-type="table" rid="THORAXJNL2013203557TB2"><offsets xml_i="27052" xml_f="27059" txt_i="15343" txt_f="15350">table 2</offsets></xref><offsets xml_i="27066" xml_f="27068" txt_i="15350" txt_f="15352">).</offsets></p><table-wrap id="THORAXJNL2013203557TB2" position="float"><label><offsets xml_i="27136" xml_f="27143" txt_i="15353" txt_f="15360">Table 2</offsets></label><caption><p><offsets xml_i="27163" xml_f="27200" txt_i="15360" txt_f="15397">The maximal post-exercise fall in FEV</offsets><sub><offsets xml_i="27205" xml_f="27206" txt_i="15397" txt_f="15398">1</offsets></sub><offsets xml_i="27212" xml_f="27503" txt_i="15398" txt_f="15689"> compared with pre-exercise values at baseline (ie, at randomisation) and after 3 and 6 weeks of treatment in the group inhaling regular placebo and terbutaline on demand, regular budesonide and terbutaline on demand and regular placebo and the combination of budesonide+formoterol on demand</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="char" char="±" span="1"></col><col align="char" char="±" span="1"></col><col align="char" char="±" span="1"></col></colgroup><thead valign="bottom"><tr><th rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="27844" xml_f="27852" txt_i="15690" txt_f="15698">Baseline</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="27898" xml_f="27905" txt_i="15698" txt_f="15705">3 weeks</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="27951" xml_f="27958" txt_i="15705" txt_f="15712">6 weeks</offsets></th></tr></thead><tbody><tr><td colspan="4" rowspan="1"><offsets xml_i="28015" xml_f="28056" txt_i="15712" txt_f="15753">Regular placebo and terbutaline on demand</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="28098" xml_f="28120" txt_i="15754" txt_f="15776"> Max post-exercise FEV</offsets><sub><offsets xml_i="28125" xml_f="28126" txt_i="15776" txt_f="15777">1</offsets></sub><offsets xml_i="28132" xml_f="28137" txt_i="15777" txt_f="15782"> fall</offsets><break></break><offsets xml_i="28152" xml_f="28172" txt_i="15782" txt_f="15802"> Relative change (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28205" xml_f="28213" txt_i="15803" txt_f="15811">17.7±8.9</offsets><break></break><offsets xml_i="28228" xml_f="28229" txt_i="15811" txt_f="15812">–</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28262" xml_f="28270" txt_i="15813" txt_f="15821">16.9±8.5</offsets><break></break><offsets xml_i="28285" xml_f="28294" txt_i="15821" txt_f="15830">−1.6±45.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28327" xml_f="28336" txt_i="15831" txt_f="15840">18.8±10.9</offsets><break></break><offsets xml_i="28351" xml_f="28360" txt_i="15840" txt_f="15849">+8.9±55.1</offsets></td></tr><tr><td colspan="4" rowspan="1"><offsets xml_i="28402" xml_f="28446" txt_i="15850" txt_f="15894">Regular budesonide and terbutaline on demand</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="28488" xml_f="28510" txt_i="15895" txt_f="15917"> Max post-exercise FEV</offsets><sub><offsets xml_i="28515" xml_f="28516" txt_i="15917" txt_f="15918">1</offsets></sub><offsets xml_i="28522" xml_f="28527" txt_i="15918" txt_f="15923"> fall</offsets><break></break><offsets xml_i="28542" xml_f="28562" txt_i="15923" txt_f="15943"> Relative change (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28595" xml_f="28603" txt_i="15944" txt_f="15952">15.3±5.7</offsets><break></break><offsets xml_i="28618" xml_f="28619" txt_i="15952" txt_f="15953">–</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28652" xml_f="28660" txt_i="15954" txt_f="15962">11.3±7.2</offsets><break></break><offsets xml_i="28675" xml_f="28684" txt_i="15962" txt_f="15971">−26.4±7.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28717" xml_f="28724" txt_i="15972" txt_f="15979">9.6±7.0</offsets><break></break><offsets xml_i="28739" xml_f="28749" txt_i="15979" txt_f="15989">−38.6±43.4</offsets></td></tr><tr><td colspan="4" rowspan="1"><offsets xml_i="28791" xml_f="28842" txt_i="15990" txt_f="16041">Regular placebo and budesonide/formoterol on demand</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="28884" xml_f="28906" txt_i="16042" txt_f="16064"> Max post-exercise FEV</offsets><sub><offsets xml_i="28911" xml_f="28912" txt_i="16064" txt_f="16065">1</offsets></sub><offsets xml_i="28918" xml_f="28923" txt_i="16065" txt_f="16070"> fall</offsets><break></break><offsets xml_i="28938" xml_f="28958" txt_i="16070" txt_f="16090"> Relative change (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28991" xml_f="28999" txt_i="16091" txt_f="16099">16.4±7.5</offsets><break></break><offsets xml_i="29014" xml_f="29015" txt_i="16099" txt_f="16100">–</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29048" xml_f="29056" txt_i="16101" txt_f="16109">12.6±7.2</offsets><break></break><offsets xml_i="29071" xml_f="29081" txt_i="16109" txt_f="16119">−18.7±42.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29114" xml_f="29122" txt_i="16120" txt_f="16128">11.1±8.2</offsets><break></break><offsets xml_i="29137" xml_f="29147" txt_i="16128" txt_f="16138">−28.5±53.7</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="29197" xml_f="29457" txt_i="16139" txt_f="16399">The exercise test is performed 24 h after the last dose of the study medication. The relative change in EIB following 3 and 6 weeks of treatment indicates the relative change in EIB after treatment compared with pre-exercise EIB. Data are presented as mean±SD.</offsets></p></fn><fn><p><offsets xml_i="29473" xml_f="29519" txt_i="16400" txt_f="16446">EIB, exercise-induced bronchoconstriction; FEV</offsets><sub><offsets xml_i="29524" xml_f="29525" txt_i="16446" txt_f="16447">1</offsets></sub><offsets xml_i="29531" xml_f="29565" txt_i="16447" txt_f="16481">, forced expiratory volume in 1 s.</offsets></p></fn></table-wrap-foot></table-wrap><fig id="THORAXJNL2013203557F2" position="float"><label><offsets xml_i="29661" xml_f="29669" txt_i="16482" txt_f="16490">Figure 2</offsets></label><caption><p><offsets xml_i="29689" xml_f="29725" txt_i="16490" txt_f="16526">Forced expiratory volume in 1 s (FEV</offsets><sub><offsets xml_i="29730" xml_f="29731" txt_i="16526" txt_f="16527">1</offsets></sub><offsets xml_i="29737" xml_f="29944" txt_i="16527" txt_f="16734">) before and after a 6 min standardised exercise test on a treadmill, while breathing dry air, before treatment (upper panel) and after 6 weeks of treatment (lower panel) with the three different treatments.</offsets></p></caption><graphic xlink:href="thoraxjnl-2013-203557f02"></graphic></fig><p><offsets xml_i="30024" xml_f="30068" txt_i="16735" txt_f="16779">The effect of treatment on post-exercise FEV</offsets><sub><offsets xml_i="30073" xml_f="30074" txt_i="16779" txt_f="16780">1</offsets></sub><offsets xml_i="30080" xml_f="30224" txt_i="16780" txt_f="16924"> fall differed between the terbutaline on-demand group and the budesonide/formoterol group (p=0.017) and the regular budesonide group (p=0.026).</offsets></p><p><offsets xml_i="30231" xml_f="30405" txt_i="16925" txt_f="17099">After 3 weeks a small reduction in EIB was observed in the budesonide/formoterol group (p=0.051) and the regular budesonide group (p=0.113) but not in the terbutaline group (</offsets><xref ref-type="table" rid="THORAXJNL2013203557TB2"><offsets xml_i="30457" xml_f="30464" txt_i="17099" txt_f="17106">table 2</offsets></xref><offsets xml_i="30471" xml_f="30473" txt_i="17106" txt_f="17108">).</offsets></p><p><offsets xml_i="30480" xml_f="30505" txt_i="17109" txt_f="17134">Maximal post-exercise FEV</offsets><sub><offsets xml_i="30510" xml_f="30511" txt_i="17134" txt_f="17135">1</offsets></sub><offsets xml_i="30517" xml_f="30786" txt_i="17135" txt_f="17404"> fall after 6 weeks was 1.2% in favour of regular budesonide treatment compared with the budesonide/formoterol on-demand group. Non-inferiority for the combination treatment on demand compared with regular budesonide treatment was proven for the main outcome variable (</offsets><xref ref-type="fig" rid="THORAXJNL2013203557F3"><offsets xml_i="30835" xml_f="30843" txt_i="17404" txt_f="17412">figure 3</offsets></xref><offsets xml_i="30850" xml_f="30852" txt_i="17412" txt_f="17414">).</offsets></p><fig id="THORAXJNL2013203557F3" position="float"><label><offsets xml_i="30912" xml_f="30920" txt_i="17415" txt_f="17423">Figure 3</offsets></label><caption><p><offsets xml_i="30940" xml_f="31176" txt_i="17423" txt_f="17659">Demonstration of non-inferiority between budesonide on a regular basis (400 μg daily) and terbutaline (0.5 mg) on demand versus the combination of budesonide (400 μg) and formoterol (6.0 μg) on demand in the per protocol population. FEV</offsets><sub><offsets xml_i="31181" xml_f="31182" txt_i="17659" txt_f="17660">1</offsets></sub></p></caption><graphic xlink:href="thoraxjnl-2013-203557f03"></graphic></fig></sec><sec id="s3c"><title><offsets xml_i="31292" xml_f="31318" txt_i="17662" txt_f="17688">Effects on other variables</offsets></title><p><offsets xml_i="31329" xml_f="31390" txt_i="17689" txt_f="17750">Asthma was well controlled after 6 weeks of treatment (ACQ5, </offsets><xref ref-type="table" rid="THORAXJNL2013203557TB3"><offsets xml_i="31442" xml_f="31449" txt_i="17750" txt_f="17757">table 3</offsets></xref><offsets xml_i="31456" xml_f="31563" txt_i="17757" txt_f="17864">). Symptom score was low on days with exercise and there were almost no symptoms on days without exercise (</offsets><xref ref-type="table" rid="THORAXJNL2013203557TB3"><offsets xml_i="31615" xml_f="31622" txt_i="17864" txt_f="17871">table 3</offsets></xref><offsets xml_i="31629" xml_f="31703" txt_i="17871" txt_f="17945">). Symptoms and ACQ scores did not differ between the groups at any visit.</offsets></p><table-wrap id="THORAXJNL2013203557TB3" position="float"><label><offsets xml_i="31771" xml_f="31778" txt_i="17946" txt_f="17953">Table 3</offsets></label><caption><p><offsets xml_i="31798" xml_f="31824" txt_i="17953" txt_f="17979">Measures of asthma control</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead valign="bottom"><tr><th rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="32138" xml_f="32196" txt_i="17980" txt_f="18038">Regular placebo once daily+budesonide/formoterol as needed</offsets><break></break><offsets xml_i="32211" xml_f="32215" txt_i="18038" txt_f="18042">N=23</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="32261" xml_f="32309" txt_i="18042" txt_f="18090">Regular placebo once daily+terbutaline as needed</offsets><break></break><offsets xml_i="32324" xml_f="32328" txt_i="18090" txt_f="18094">N=22</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="32374" xml_f="32425" txt_i="18094" txt_f="18145">Regular budesonide once daily+terbutaline as needed</offsets><break></break><offsets xml_i="32440" xml_f="32444" txt_i="18145" txt_f="18149">N=21</offsets></th></tr></thead><tbody><tr><td colspan="4" rowspan="1"><offsets xml_i="32501" xml_f="32505" txt_i="18149" txt_f="18153">ACQ5</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32547" xml_f="32556" txt_i="18154" txt_f="18163"> Baseline</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32589" xml_f="32596" txt_i="18164" txt_f="18171">1.2±0.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32629" xml_f="32636" txt_i="18172" txt_f="18179">1.3±0.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32669" xml_f="32676" txt_i="18180" txt_f="18187">1.0±0.6</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32718" xml_f="32732" txt_i="18188" txt_f="18202"> After 6 weeks</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32765" xml_f="32774" txt_i="18203" txt_f="18212">0.75±0.58</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32807" xml_f="32816" txt_i="18213" txt_f="18222">0.93±0.74</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32849" xml_f="32858" txt_i="18223" txt_f="18232">0.66±0.61</offsets></td></tr><tr><td colspan="4" rowspan="1"><offsets xml_i="32900" xml_f="32933" txt_i="18233" txt_f="18266">Symptoms associated with exercise</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32975" xml_f="32996" txt_i="18267" txt_f="18288"> Asthma symptoms (%)*</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33029" xml_f="33038" txt_i="18289" txt_f="18298">49.8±26.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33071" xml_f="33080" txt_i="18299" txt_f="18308">50.9±36.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33113" xml_f="33122" txt_i="18309" txt_f="18318">51.1±30.5</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="33164" xml_f="33176" txt_i="18319" txt_f="18331"> Cough (0–4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33209" xml_f="33218" txt_i="18332" txt_f="18341">0.31±0.24</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33251" xml_f="33260" txt_i="18342" txt_f="18351">0.26±0.31</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33293" xml_f="33302" txt_i="18352" txt_f="18361">0.22±0.25</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="33344" xml_f="33357" txt_i="18362" txt_f="18375"> Wheeze (0–4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33390" xml_f="33399" txt_i="18376" txt_f="18385">0.29±0.35</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33432" xml_f="33441" txt_i="18386" txt_f="18395">0.31±0.56</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33474" xml_f="33483" txt_i="18396" txt_f="18405">0.20±0.26</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="33525" xml_f="33551" txt_i="18406" txt_f="18432"> Shortness of breath (0–4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33584" xml_f="33593" txt_i="18433" txt_f="18442">0.42±0.48</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33626" xml_f="33635" txt_i="18443" txt_f="18452">0.63±0.77</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33668" xml_f="33677" txt_i="18453" txt_f="18462">0.37±0.47</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="33719" xml_f="33731" txt_i="18463" txt_f="18475"> Mucus (0–4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33764" xml_f="33773" txt_i="18476" txt_f="18485">0.33±0.28</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33806" xml_f="33815" txt_i="18486" txt_f="18495">0.52±0.66</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33848" xml_f="33857" txt_i="18496" txt_f="18505">0.59±0.78</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="33899" xml_f="33920" txt_i="18506" txt_f="18527"> Breathlessness (0–4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33953" xml_f="33962" txt_i="18528" txt_f="18537">0.69±0.62</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33995" xml_f="34004" txt_i="18538" txt_f="18547">0.95±1.03</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34037" xml_f="34046" txt_i="18548" txt_f="18557">0.82±0.75</offsets></td></tr><tr><td colspan="4" rowspan="1"><offsets xml_i="34088" xml_f="34125" txt_i="18558" txt_f="18595">Symptoms not associated with exercise</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="34167" xml_f="34188" txt_i="18596" txt_f="18617"> Asthma symptoms (%)*</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34221" xml_f="34230" txt_i="18618" txt_f="18627">0.69±0.62</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34263" xml_f="34272" txt_i="18628" txt_f="18637">0.95±1.03</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34305" xml_f="34314" txt_i="18638" txt_f="18647">0.82±0.75</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="34356" xml_f="34368" txt_i="18648" txt_f="18660"> Cough (0–4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34401" xml_f="34410" txt_i="18661" txt_f="18670">0.13±0.30</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34443" xml_f="34452" txt_i="18671" txt_f="18680">0.22±0.39</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34485" xml_f="34494" txt_i="18681" txt_f="18690">0.08±0.16</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="34536" xml_f="34549" txt_i="18691" txt_f="18704"> Wheeze (0–4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34582" xml_f="34591" txt_i="18705" txt_f="18714">0.06±0.14</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34624" xml_f="34633" txt_i="18715" txt_f="18724">0.07±0.22</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34666" xml_f="34675" txt_i="18725" txt_f="18734">0.02±0.06</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="34717" xml_f="34743" txt_i="18735" txt_f="18761"> Shortness of breath (0–4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34776" xml_f="34785" txt_i="18762" txt_f="18771">0.06±0.15</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34818" xml_f="34827" txt_i="18772" txt_f="18781">0.12±0.24</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34860" xml_f="34869" txt_i="18782" txt_f="18791">0.03±0.05</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="34911" xml_f="34923" txt_i="18792" txt_f="18804"> Mucus (0–4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34956" xml_f="34965" txt_i="18805" txt_f="18814">0.08±0.23</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34998" xml_f="35007" txt_i="18815" txt_f="18824">0.14±0.27</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35040" xml_f="35049" txt_i="18825" txt_f="18834">0.11±0.29</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="35091" xml_f="35112" txt_i="18835" txt_f="18856"> Breathlessness (0–4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35145" xml_f="35154" txt_i="18857" txt_f="18866">0.07±0.15</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35187" xml_f="35196" txt_i="18867" txt_f="18876">0.14±0.18</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35229" xml_f="35238" txt_i="18877" txt_f="18886">0.06±0.16</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="35288" xml_f="35464" txt_i="18887" txt_f="19063">ACQ5 at baseline and after 6 weeks of treatment and symptom score (according to the electronic diary, averaged for the period of 6 weeks) during days with and without exercise.</offsets></p></fn><fn><p><offsets xml_i="35480" xml_f="35897" txt_i="19064" txt_f="19481">*Asthma symptoms associated with exercise are calculated on days when exercise was performed. Asthma symptoms not associated with exercise indicate days with any symptom not related to exercise during the whole period of 6 weeks. Cough, wheeze, shortness of breath, mucus and breathlessness are indicated on a scale from 0 to 4, where 0 relates to no symptoms and 4 to maximal symptoms. Data are presented as mean±SD.</offsets></p></fn><fn><p><offsets xml_i="35913" xml_f="35950" txt_i="19482" txt_f="19519">ACQ5, Asthma Control Questionnaire 5.</offsets></p></fn></table-wrap-foot></table-wrap><p><offsets xml_i="35993" xml_f="36147" txt_i="19520" txt_f="19674">The daily dose of inhaled budesonide was on average 393 μg in the regular budesonide group and 163 μg in the group who inhaled the combination on demand (</offsets><xref ref-type="table" rid="THORAXJNL2013203557TB4"><offsets xml_i="36199" xml_f="36206" txt_i="19674" txt_f="19681">table 4</offsets></xref><offsets xml_i="36213" xml_f="36322" txt_i="19681" txt_f="19790">). The need for extra medication, prior to exercise and for symptom relief, was similar in the three groups (</offsets><xref ref-type="table" rid="THORAXJNL2013203557TB4"><offsets xml_i="36374" xml_f="36381" txt_i="19790" txt_f="19797">table 4</offsets></xref><offsets xml_i="36388" xml_f="36390" txt_i="19797" txt_f="19799">).</offsets></p><table-wrap id="THORAXJNL2013203557TB4" position="float"><label><offsets xml_i="36458" xml_f="36465" txt_i="19800" txt_f="19807">Table 4</offsets></label><caption><p><offsets xml_i="36485" xml_f="36527" txt_i="19807" txt_f="19849">Intake of study drugs throughout the study</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead valign="bottom"><tr><th rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="36841" xml_f="36895" txt_i="19850" txt_f="19904">Placebo once daily and budesonide+formoterol on demand</offsets><break></break><offsets xml_i="36910" xml_f="36914" txt_i="19904" txt_f="19908">N=23</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="36960" xml_f="37008" txt_i="19908" txt_f="19956">Regular placebo once daily+terbutaline on demand</offsets><break></break><offsets xml_i="37023" xml_f="37027" txt_i="19956" txt_f="19960">N=22</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="37073" xml_f="37124" txt_i="19960" txt_f="20011">Regular budesonide once daily+terbutaline on demand</offsets><break></break><offsets xml_i="37139" xml_f="37143" txt_i="20011" txt_f="20015">N=21</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="37200" xml_f="37251" txt_i="20015" txt_f="20066">Budesonide, metered dose 400 μg/inhalation (μg/day)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37284" xml_f="37285" txt_i="20067" txt_f="20068">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37318" xml_f="37319" txt_i="20069" txt_f="20070">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37352" xml_f="37358" txt_i="20071" txt_f="20077">393±12</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="37400" xml_f="37451" txt_i="20078" txt_f="20129">Budesonide, metered dose 200 μg/inhalation (μg/day)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37484" xml_f="37490" txt_i="20130" txt_f="20136">163±80</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37523" xml_f="37524" txt_i="20137" txt_f="20138">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37557" xml_f="37558" txt_i="20139" txt_f="20140">0</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="37600" xml_f="37620" txt_i="20141" txt_f="20161">Terbutaline (μg/day)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37653" xml_f="37654" txt_i="20162" txt_f="20163">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37687" xml_f="37694" txt_i="20164" txt_f="20171">372±216</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37727" xml_f="37734" txt_i="20172" txt_f="20179">309±266</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="37776" xml_f="37795" txt_i="20180" txt_f="20199">Formoterol (μg/day)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37828" xml_f="37835" txt_i="20200" txt_f="20207">3.7±2.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37868" xml_f="37869" txt_i="20208" txt_f="20209">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37902" xml_f="37903" txt_i="20210" txt_f="20211">0</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="37945" xml_f="37983" txt_i="20212" txt_f="20250">Maintenance, number of inhalations/day</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38016" xml_f="38025" txt_i="20251" txt_f="20260">0.96±0.10</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38058" xml_f="38067" txt_i="20261" txt_f="20270">0.99±0.03</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38100" xml_f="38109" txt_i="20271" txt_f="20280">0.98±0.03</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="38151" xml_f="38206" txt_i="20281" txt_f="20336">Medication prior to exercise, number of inhalations/day</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38239" xml_f="38248" txt_i="20337" txt_f="20346">0.74±0.46</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38281" xml_f="38290" txt_i="20347" txt_f="20356">0.78±0.46</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38323" xml_f="38332" txt_i="20357" txt_f="20366">0.63±0.19</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="38374" xml_f="38430" txt_i="20367" txt_f="20423">Medication for symptom relief, number of inhalations/day</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38463" xml_f="38472" txt_i="20424" txt_f="20433">0.07±0.09</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38505" xml_f="38514" txt_i="20434" txt_f="20443">0.15±0.24</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38547" xml_f="38556" txt_i="20444" txt_f="20453">0.14±0.55</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="38606" xml_f="39057" txt_i="20454" txt_f="20905">The dose of budesonide is calculated as the metered dose which is 400 μg/inhalation in the group who inhaled budesonide on a regular basis and 200 μg/inhalation in the group who inhaled the combination of budesonide and formoterol as needed. ‘On demand’ medication before exercise was inhaled four to five times per week whereas ‘on demand’ medication on days without exercise was taken once per week or per second week. Data are presented as mean±SD.</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="s3d"><title><offsets xml_i="39124" xml_f="39130" txt_i="20907" txt_f="20913">Safety</offsets></title><p><offsets xml_i="39141" xml_f="39431" txt_i="20914" txt_f="21204">All treatments were well tolerated and no drug-related adverse events or serious adverse events were reported. No patient discontinued treatment due to an adverse event. The most common adverse events reported by the patients (n=66) were common cold, cough, sore throat and gastroenteritis.</offsets></p></sec></sec><sec sec-type="discussion" id="s4"><title><offsets xml_i="39489" xml_f="39499" txt_i="21207" txt_f="21217">Discussion</offsets></title><p><offsets xml_i="39510" xml_f="40203" txt_i="21218" txt_f="21911">In this study it was demonstrated that a 6-week treatment regimen with inhalation of a combination of budesonide and formoterol on demand was superior to on-demand inhalation of a SABA in reducing EIB, assessed by an exercise test performed after a 24 h period free from any medication. Furthermore, the reduction in EIB after 6 weeks of treatment with inhaled budesonide/formoterol on demand was non-inferior to daily inhalation of budesonide. This finding clearly indicates that treatment with three to four doses per week of the combination is sufficient to provide good asthma control, implying no need for regular treatment with inhaled corticosteroids (ICS) in patients with mild asthma.</offsets></p><p><offsets xml_i="40210" xml_f="40291" txt_i="21912" txt_f="21993">According to current guidelines, patients with EIB should inhale a rapid-acting β</offsets><sub><offsets xml_i="40296" xml_f="40297" txt_i="21993" txt_f="21994">2</offsets></sub><offsets xml_i="40303" xml_f="40448" txt_i="21994" txt_f="22139"> agonist prior to exercise and if reliever medication is needed more than twice a week, regular controller therapy with ICS should be considered.</offsets><xref rid="R1" ref-type="bibr"><offsets xml_i="40479" xml_f="40480" txt_i="22139" txt_f="22140">1</offsets></xref><offsets xml_i="40487" xml_f="40705" txt_i="22140" txt_f="22358"> Our study included patients with mild asthma in whom inhaled steroids were not indicated according to the treating physician and who inhaled reliever medication up to four times a week. These patients often inhale a β</offsets><sub><offsets xml_i="40710" xml_f="40711" txt_i="22358" txt_f="22359">2</offsets></sub><offsets xml_i="40717" xml_f="41293" txt_i="22359" txt_f="22935"> agonist before exercise as routine, implying that the exact need for treatment is not known. In clinical practice these patients are frequently treated with a rapid SABA or LABA on demand as the only medication. In the present study all three groups of patients seemed have well controlled asthma from a clinical point of view, as their consumption of extra medication was approximately one inhalation per week or every second week. This shows that the favourable result obtained in the budesonide/formoterol group cannot be explained by a higher number of extra inhalations.</offsets></p><p><offsets xml_i="41300" xml_f="42052" txt_i="22936" txt_f="23688">Although terbutaline protected against EIB when inhaled on demand throughout the study, as indicated by the low symptom scores even on exercise days, the bronchial response to exercise was unaltered, or even slightly increased, after 6 weeks of treatment with inhaled terbutaline on demand as monotherapy. As the symptom scores did not differ between groups on the exercise days, the patients did not seem to perceive a difference in the protective effect between terbutaline and budesonide/formoterol when inhaled prior to exercise. However, the results clearly indicate that treatment with the combination on demand provides better protection for occasional, unplanned exertion than terbutaline on demand as monotherapy. Continuous treatment with a β</offsets><sub><offsets xml_i="42057" xml_f="42058" txt_i="23688" txt_f="23689">2</offsets></sub><offsets xml_i="42064" xml_f="42124" txt_i="23689" txt_f="23749"> agonist may increase the bronchial response to methacholine</offsets><xref rid="R17" ref-type="bibr"><offsets xml_i="42156" xml_f="42158" txt_i="23749" txt_f="23751">17</offsets></xref><offsets xml_i="42165" xml_f="42179" txt_i="23751" txt_f="23765"> and exercise.</offsets><xref rid="R18" ref-type="bibr"><offsets xml_i="42211" xml_f="42213" txt_i="23765" txt_f="23767">18</offsets></xref><offsets xml_i="42220" xml_f="42430" txt_i="23767" txt_f="23977"> In addition, the enhancement of bronchial response to methacholine induced by repeated low-dose allergen challenges is counteracted by inhalation of a combination of a steroid (budesonide) and a rapid-acting β</offsets><sub><offsets xml_i="42435" xml_f="42436" txt_i="23977" txt_f="23978">2</offsets></sub><offsets xml_i="42442" xml_f="42506" txt_i="23978" txt_f="24042"> agonist (formoterol) but not by inhalation of formoterol alone.</offsets><xref rid="R19" ref-type="bibr"><offsets xml_i="42538" xml_f="42540" txt_i="24042" txt_f="24044">19</offsets></xref><offsets xml_i="42547" xml_f="42622" txt_i="24044" txt_f="24119"> There are thus a number of studies showing that regular treatment with a β</offsets><sub><offsets xml_i="42627" xml_f="42628" txt_i="24119" txt_f="24120">2</offsets></sub><offsets xml_i="42634" xml_f="42786" txt_i="24120" txt_f="24272"> agonist alone has no beneficial effect on airway responsiveness over time. The present study is in agreement with these findings, as treatment with a β</offsets><sub><offsets xml_i="42791" xml_f="42792" txt_i="24272" txt_f="24273">2</offsets></sub><offsets xml_i="42798" xml_f="42904" txt_i="24273" txt_f="24379"> agonist alone did not alter airways response to exercise over time. We conclude that monotherapy with a β</offsets><sub><offsets xml_i="42909" xml_f="42910" txt_i="24379" txt_f="24380">2</offsets></sub><offsets xml_i="42916" xml_f="42997" txt_i="24380" txt_f="24461"> agonist on demand, which is not indicated for regular use in more severe asthma,</offsets><xref rid="R20" ref-type="bibr"><offsets xml_i="43029" xml_f="43034" txt_i="24461" txt_f="24466">20–22</offsets></xref><offsets xml_i="43041" xml_f="43091" txt_i="24466" txt_f="24516"> may also be avoided in patients with mild asthma.</offsets></p><p><offsets xml_i="43098" xml_f="43603" txt_i="24517" txt_f="25022">In our study, the long-term protective effect on EIB was similar in the groups who received budesonide, demonstrating that budesonide+formoterol inhaled on demand was non-inferior to regular, daily corticosteroid therapy, despite a 2.5-fold lower total corticosteroid dose. The combination of budesonide and formoterol, used as maintenance and reliever therapy, prevents exacerbations and symptoms more effectively than regular inhalations of the combination with rapid-acting bronchodilators as reliever.</offsets><xref rid="R23" ref-type="bibr"><offsets xml_i="43635" xml_f="43640" txt_i="25022" txt_f="25027">23–26</offsets></xref><offsets xml_i="43647" xml_f="44222" txt_i="25027" txt_f="25602"> In all these studies the ICS/LABA combination has been given as maintenance and as reliever therapy. This treatment strategy has been used in subjects with more severe asthma, that is, in patients who need regular treatment with a combination of inhaled steroids and LABAs. For the first time it was shown that on-demand use of an ICS/LABA combination is non-inferior to regular treatment with an ICS in patients with asthma and EIB, indicating that treatment with the combination on demand is an alternative to regular corticosteroid treatment in patients with mild asthma.</offsets></p><p><offsets xml_i="44229" xml_f="44630" txt_i="25603" txt_f="26004">It could be argued that 6 weeks of treatment may be too short to achieve the full effect of the steroid on EIB and that the dose of budesonide may be too low to achieve maximal effect. In a 3-month study of children with a history of wheezing, but not documented EIB, a daily dose of 400 μg of beclomethasone dipropionate totally abolished post-exercise bronchoconstriction after 1 month of treatment.</offsets><xref rid="R27" ref-type="bibr"><offsets xml_i="44662" xml_f="44664" txt_i="26004" txt_f="26006">27</offsets></xref><offsets xml_i="44671" xml_f="44764" txt_i="26006" txt_f="26099"> Six weeks of inhaled budesonide, 1600 μg daily, reduced EIB compared with placebo in adults.</offsets><xref rid="R28" ref-type="bibr"><offsets xml_i="44796" xml_f="44798" txt_i="26099" txt_f="26101">28</offsets></xref><offsets xml_i="44805" xml_f="44872" txt_i="26101" txt_f="26168"> In children with asthma EIB was reduced after 3 weeks of treatment</offsets><xref rid="R29" ref-type="bibr"><offsets xml_i="44904" xml_f="44906" txt_i="26168" txt_f="26170">29</offsets></xref><offsets xml_i="44913" xml_f="45021" txt_i="26170" txt_f="26278"> and in another paediatric study a daily dose of 200 μg fluticasone reduced EIB within 4 weeks of treatment.</offsets><xref rid="R30" ref-type="bibr"><offsets xml_i="45053" xml_f="45055" txt_i="26278" txt_f="26280">30</offsets></xref><offsets xml_i="45062" xml_f="45222" txt_i="26280" txt_f="26440"> The effect of inhaled steroids on EIB thus appears after a few weeks of treatment, indicating that 6 weeks of treatment is sufficient for a study of this type.</offsets></p><p><offsets xml_i="45229" xml_f="45358" txt_i="26441" txt_f="26570">A high dose of budesonide (1600 μg/day) reduced EIB by 17% in adult patients with asthma who had a pretreatment post-exercise FEV</offsets><sub><offsets xml_i="45363" xml_f="45364" txt_i="26570" txt_f="26571">1</offsets></sub><offsets xml_i="45370" xml_f="45383" txt_i="26571" txt_f="26584"> fall of 26%.</offsets><xref rid="R28" ref-type="bibr"><offsets xml_i="45415" xml_f="45417" txt_i="26584" txt_f="26586">28</offsets></xref><offsets xml_i="45424" xml_f="45459" txt_i="26586" txt_f="26621"> In our study the post-exercise FEV</offsets><sub><offsets xml_i="45464" xml_f="45465" txt_i="26621" txt_f="26622">1</offsets></sub><offsets xml_i="45471" xml_f="46077" txt_i="26622" txt_f="27228"> fall prior to randomisation was 15–18%, indicating that the patients had mild asthma and there was not much room for improvement. Although studies in children clearly indicate that the effect of inhaled steroids on EIB appears at low doses, we cannot exclude the possibility that a higher dose of budesonide in the group that received regular treatment would have improved the results further. The present data do not allow any conclusions to be drawn regarding possible dose–response relationships between on-demand medication with the combination of budesonide/formoterol and the protection against EIB.</offsets></p><p><offsets xml_i="46084" xml_f="46186" txt_i="27229" txt_f="27331">In conclusion, in mild asthma a combination of an inhaled corticosteroid and a long and rapid-acting β</offsets><sub><offsets xml_i="46191" xml_f="46192" txt_i="27331" txt_f="27332">2</offsets></sub><offsets xml_i="46198" xml_f="46560" txt_i="27332" txt_f="27694"> agonist used on demand is superior to the use of an inhaled SABA alone in reducing EIB. In addition, inhalation of the combination on demand is not inferior to regular treatment with the corticosteroid alone in these patients, despite a 2.5-fold lower dose of the steroid. The results may have implications for treatment guidelines in patients with mild asthma.</offsets></p></sec></body><back><fn-group><fn><p><bold>Contributors:</bold> KL: study design. NL, BD, LB, TP, GH and KHC: patient recruitment, enrolment, randomisation and follow-up. LJ and TE: collection of data. LJ: statistical analysis. NL, LJ, TE, GH, TP, LB, BD, KHC and KL: analysis, interpretation of the data and writing of the manuscript.</p></fn><fn><p><bold>Funding:</bold> The study was sponsored by Astra Zeneca.</p></fn><fn><p><bold>Competing interests:</bold> NL has served as a speaker and/or participated in education arranged by Takeda. LB has, during the past 5 years, on one or more occasion served on an advisory board and/or served as a speaker and/or participated in education arranged by Aersonett, Aerocrine, Almirall, Andre-Pharma-Chiesi, AstraZeneca, Boehringer Ingelheim, GSK, Meda, MSD, Niigard, Nycomed, Novartis and Takeda. BD has, during the past 5 years, on one or more occasion served on an advisory board and/or served as a speaker and/or participated in education arranged by Actelion, Meda and Novartis. TP has, during the past 5 years, on one or more occasion served on an advisory board for MSD and served as a speaker in education arranged by Meda, GSK and ALK. GH has in relation to this paper no conflict of interest. KHC has no conflict of interest related to the present manuscript. He has served on consultatory boards over the past 3 years for Boehringer – Ingelheim, Meda and Nycomed. He has given lectures for Boehringer – Ingelheim, Meda, Nycomed and Merck. He has received unrestricted research grants from The Norwegian Health Authority South-East. KL has, during the past 5 years, on one or more occasion served on an advisory board and/or served as a speaker and/or participated in education arranged by AstraZeneca, Boehringer Ingelheim, GSK, Meda, MSD, Nycomed, Novartis, Takeda, and Pfizer. Kjell Larsson has also received unrestricted research grants from AstraZeneca, Boehringer Ingelheim, and GSK.</p></fn><fn><p><bold>Patient consent:</bold> Obtained.</p></fn><fn><p><bold>Ethics approval:</bold> The Ethics Committee of Stockholm (D5890L00032) and the Regional Ethics Committee of Health Region South East of Norway.</p></fn><fn><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="other"><article-title>Global strategy for asthma management and prevention</article-title>. <year>2011</year>
<comment><ext-link ext-link-type="uri" xlink:href="http://www.ginasthma.org">http://www.ginasthma.org</ext-link></comment></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>JP</given-names></name><name><surname>Craig</surname><given-names>TJ</given-names></name><name><surname>Stoloff</surname><given-names>SW</given-names></name><etal></etal></person-group>
<article-title>Impact of exercise-related respiratory symptoms in adults with asthma: Exercise-Induced Bronchospasm Landmark National Survey</article-title>. <source>Allergy Asthma Proc</source>
<year>2011</year>;<volume>32</volume>:<fpage>431</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">22221437</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vahlkvist</surname><given-names>S</given-names></name><name><surname>Inman</surname><given-names>MD</given-names></name><name><surname>Pedersen</surname><given-names>S</given-names></name></person-group>
<article-title>Effect of asthma treatment on fitness, daily activity and body composition in children with asthma</article-title>. <source>Allergy</source>
<year>2010</year>;<volume>65</volume>:<fpage>1464</fpage>–<lpage>71</lpage><pub-id pub-id-type="pmid">20557298</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>RS</given-names></name><name><surname>Wharton</surname><given-names>MJ</given-names></name><name><surname>Buston</surname><given-names>MH</given-names></name></person-group>
<article-title>The place of physical exercise and bronchodilator drugs in the assessment of the asthmatic child</article-title>. <source>Arch Dis Child</source>
<year>1963</year>;<volume>38</volume>:<fpage>539</fpage>–<lpage>45</lpage><pub-id pub-id-type="pmid">14090375</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>D</given-names></name><name><surname>Timmers</surname><given-names>MC</given-names></name><name><surname>Zwinderman</surname><given-names>AH</given-names></name><etal></etal></person-group>
<article-title>Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma</article-title>. <source>N Engl J Med</source>
<year>1992</year>;<volume>327</volume>:<fpage>1198</fpage>–<lpage>203</lpage><pub-id pub-id-type="pmid">1357550</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Connor</surname><given-names>BJ</given-names></name><name><surname>Aikman</surname><given-names>SL</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group>
<article-title>Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma</article-title>. <source>N Engl J Med</source>
<year>1992</year>;<volume>327</volume>:<fpage>1204</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">1357551</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramage</surname><given-names>L</given-names></name><name><surname>Lipworth</surname><given-names>BJ</given-names></name><name><surname>Ingram</surname><given-names>CG</given-names></name><etal></etal></person-group>
<article-title>Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol</article-title>. <source>Respir Med</source>
<year>1994</year>;<volume>88</volume>:<fpage>363</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">7913549</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simons</surname><given-names>FE</given-names></name><name><surname>Gerstner</surname><given-names>TV</given-names></name><name><surname>Cheang</surname><given-names>MS</given-names></name></person-group>
<article-title>Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment</article-title>. <source>Pediatrics</source>
<year>1997</year>;<volume>99</volume>:<fpage>655</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">9113940</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cockcroft</surname><given-names>DW</given-names></name><name><surname>McParland</surname><given-names>CP</given-names></name><name><surname>Britto</surname><given-names>SA</given-names></name><etal></etal></person-group>
<article-title>Regular inhaled salbutamol and airway responsiveness to allergen</article-title>. <source>Lancet</source>
<year>1993</year>;<volume>342</volume>:<fpage>833</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">8104272</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crapo</surname><given-names>RO</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Coates</surname><given-names>AL</given-names></name><etal></etal></person-group>
<article-title>Guidelines for methacholine and exercise challenge testing—1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2000</year>;<volume>161</volume>:<fpage>309</fpage>–<lpage>29</lpage><pub-id pub-id-type="pmid">10619836</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quanjer</surname><given-names>PH</given-names></name><name><surname>Tammeling</surname><given-names>GJ</given-names></name><name><surname>Cotes</surname><given-names>JE</given-names></name><etal></etal></person-group>
<article-title>Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society</article-title>. <source>Eur Respir J Suppl</source>
<year>1993</year>;<volume>16</volume>:<fpage>5</fpage>–<lpage>40</lpage><pub-id pub-id-type="pmid">8499054</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solymar</surname><given-names>L</given-names></name><name><surname>Aronsson</surname><given-names>PH</given-names></name><name><surname>Bake</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Nitrogen single breath test, flow–volume curves and spirometry in healthy children, 7–18 years of age</article-title>. <source>Eur J Respir Dis</source>
<year>1980</year>;<volume>61</volume>:<fpage>275</fpage>–<lpage>86</lpage><pub-id pub-id-type="pmid">7202600</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><collab>American Thoracic Society</collab>
<article-title>Standardization of spirometry, 1994 update</article-title>. <source>Am J Respir Crit Care Med</source>
<year>1995</year>;<volume>152</volume>:<fpage>1107</fpage>–<lpage>36</lpage><pub-id pub-id-type="pmid">7663792</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borg</surname><given-names>E</given-names></name><name><surname>Kaijser</surname><given-names>L</given-names></name></person-group>
<article-title>A comparison between three rating scales for perceived exertion and two different work tests</article-title>. <source>Scand J Med Sci Sports</source>
<year>2006</year>;<volume>16</volume>:<fpage>57</fpage>–<lpage>69</lpage><pub-id pub-id-type="pmid">16430682</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juniper</surname><given-names>EF</given-names></name><name><surname>Svensson</surname><given-names>K</given-names></name><name><surname>Mork</surname><given-names>AC</given-names></name><etal></etal></person-group>
<article-title>Measurement properties and interpretation of three shortened versions of the Asthma Control Questionnaire</article-title>. <source>Respir Med</source>
<year>2005</year>;<volume>99</volume>:<fpage>553</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">15823451</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonasson</surname><given-names>G</given-names></name><name><surname>Carlsen</surname><given-names>KH</given-names></name><name><surname>Hultquist</surname><given-names>C</given-names></name></person-group>
<article-title>Low-dose budesonide improves exercise-induced bronchospasm in schoolchildren</article-title>. <source>Pediatr Allergy Immunol</source>
<year>2000</year>;<volume>11</volume>:<fpage>120</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">10893016</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vathenen</surname><given-names>AS</given-names></name><name><surname>Knox</surname><given-names>AJ</given-names></name><name><surname>Higgins</surname><given-names>BG</given-names></name><etal></etal></person-group>
<article-title>Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline</article-title>. <source>Lancet</source>
<year>1988</year>;<volume>1</volume>:<fpage>554</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">2894492</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hancox</surname><given-names>RJ</given-names></name><name><surname>Subbarao</surname><given-names>P</given-names></name><name><surname>Kamada</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Beta2-agonist tolerance and exercise-induced bronchospasm</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2002</year>;<volume>165</volume>:<fpage>1068</fpage>–<lpage>70</lpage><pub-id pub-id-type="pmid">11956046</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlen</surname><given-names>B</given-names></name><name><surname>Lantz</surname><given-names>AS</given-names></name><name><surname>Ihre</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Effect of formoterol with or without budesonide in repeated low-dose allergen challenge</article-title>. <source>Eur Respir J</source>
<year>2009</year>;<volume>33</volume>:<fpage>747</fpage>–<lpage>53</lpage><pub-id pub-id-type="pmid">19129280</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>HS</given-names></name><name><surname>Weiss</surname><given-names>ST</given-names></name><name><surname>Bleecker</surname><given-names>ER</given-names></name><etal></etal></person-group>
<article-title>The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol</article-title>. <source>Chest</source>
<year>2006</year>;<volume>129</volume>:<fpage>15</fpage>–<lpage>26</lpage><pub-id pub-id-type="pmid">16424409</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salpeter</surname><given-names>SR</given-names></name><name><surname>Buckley</surname><given-names>NS</given-names></name><name><surname>Ormiston</surname><given-names>TM</given-names></name><etal></etal></person-group>
<article-title>Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths</article-title>. <source>Ann Intern Med</source>
<year>2006</year>;<volume>144</volume>:<fpage>904</fpage>–<lpage>12</lpage><pub-id pub-id-type="pmid">16754916</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spitzer</surname><given-names>WO</given-names></name><name><surname>Suissa</surname><given-names>S</given-names></name><name><surname>Ernst</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>The use of beta-agonists and the risk of death and near death from asthma</article-title>. <source>N Engl J Med</source>
<year>1992</year>;<volume>326</volume>:<fpage>501</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">1346340</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Byrne</surname><given-names>PM</given-names></name><name><surname>Bisgaard</surname><given-names>H</given-names></name><name><surname>Godard</surname><given-names>PP</given-names></name><etal></etal></person-group>
<article-title>Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2005</year>;<volume>171</volume>:<fpage>129</fpage>–<lpage>36</lpage><pub-id pub-id-type="pmid">15502112</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelmeier</surname><given-names>C</given-names></name><name><surname>D'Urzo</surname><given-names>A</given-names></name><name><surname>Pauwels</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?</article-title>
<source>Eur Respir J</source>
<year>2005</year>;<volume>26</volume>:<fpage>819</fpage>–<lpage>28</lpage><pub-id pub-id-type="pmid">16264042</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bisgaard</surname><given-names>H</given-names></name><name><surname>Le Roux</surname><given-names>P</given-names></name><name><surname>Bjamer</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma</article-title>. <source>Chest</source>
<year>2006</year>;<volume>130</volume>:<fpage>1733</fpage>–<lpage>43</lpage><pub-id pub-id-type="pmid">17166990</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>SJ</given-names></name><name><surname>von Maltzahn</surname><given-names>R</given-names></name><name><surname>Naya</surname><given-names>IP</given-names></name><etal></etal></person-group>
<article-title>Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials</article-title>. <source>Int J Clin Pract</source>
<year>2010</year>;<volume>64</volume>:<fpage>619</fpage>–<lpage>27</lpage><pub-id pub-id-type="pmid">20456215</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freezer</surname><given-names>NJ</given-names></name><name><surname>Croasdell</surname><given-names>H</given-names></name><name><surname>Doull</surname><given-names>IJ</given-names></name><etal></etal></person-group>
<article-title>Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze</article-title>. <source>Eur Respir J</source>
<year>1995</year>;<volume>8</volume>:<fpage>1488</fpage>–<lpage>93</lpage><pub-id pub-id-type="pmid">8575573</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vathenen</surname><given-names>AS</given-names></name><name><surname>Knox</surname><given-names>AJ</given-names></name><name><surname>Wisniewski</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Effect of inhaled budesonide on bronchial reactivity to histamine, exercise, and eucapnic dry air hyperventilation in patients with asthma</article-title>. <source>Thorax</source>
<year>1991</year>;<volume>46</volume>:<fpage>811</fpage>–<lpage>16</lpage><pub-id pub-id-type="pmid">1771604</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofstra</surname><given-names>WB</given-names></name><name><surname>Neijens</surname><given-names>HJ</given-names></name><name><surname>Duiverman</surname><given-names>EJ</given-names></name><etal></etal></person-group>
<article-title>Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma</article-title>. <source>Pediatr Pulmonol</source>
<year>2000</year>;<volume>29</volume>:<fpage>415</fpage>–<lpage>23</lpage><pub-id pub-id-type="pmid">10821721</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>R</given-names></name><name><surname>Agertoft</surname><given-names>L</given-names></name><name><surname>Pedersen</surname><given-names>S</given-names></name></person-group>
<article-title>Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma</article-title>. <source>Eur Respir J</source>
<year>2004</year>;
<volume>24</volume>:<fpage>932</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">15572534</pub-id></mixed-citation></ref></ref-list></back></article>